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http“Off-the-shelf” devices for complex aortic
aneurysm repair
Mark A. Farber, MD, FACS, Raghuveer Vallabhaneni, MD, and William A. Marston, MD, Chapel Hill, NC
Background: Fenestrated devices currently require a 3- to 4-week manufacturing period before implantation; as such,
there have been efforts to develop “off-the-shelf” (OTS) devices to reduce the time before deﬁnitive treatment can be
accomplished. We examined all patients treated for complex aortic problems at our institution during the past 12 months
to evaluate the suitability and early outcomes of the OTS devices vs commercially available endovascular options.
Methods: Between July 2012 and September 2013, patients undergoing aortic aneurysm repair were extracted from a
prospectively managed aortic database. Two OTS devices, the Cook (Bloomington, Ind) p-Branch and the Endologix
(Irvine, Calif) Ventana device, were being evaluated through clinical trials during this time frame. The custom Cook
Zenith fenestrated endovascular (ZFEN) device was also available and approved by the U.S. Food and Drug Adminis-
tration (FDA) during the study period.
Results: Of 224 aortic aneurysms treated at our institution during this period, there were a total of 85 patients with type
IV thoracoabdominal aneurysms including juxtarenal aneurysms. Only 23 patients (27%) met anatomic criteria for OTS
devices, with 16 patients having these investigational devices implanted. The major exclusion criterion for the p-Branch
device was renal axial or circumferential position; the limiting factor for Ventana was infrasuperior mesenteric artery neck
length restriction. Five of the patients who would have ﬁt criteria for an OTS device had an FDA-approved (ZFEN) device
implanted instead, and two patients opted for open repair as a result of follow-up requirements. An additional 25 patients
received custom-designed (ZFEN) devices (n[ 30; 35%), whereas 37 (44%) others did not meet criteria for any available
endovascular device and were repaired with alternative management strategies. The mean age and maximal aortic
diameter of the two cohorts (OTS and ZFEN) were 71.8 years and 72.7 years (P[NS) and 61.3 mm and 58.5 mm (P[
NS), respectively. Technical success was 100%, with an overall 30-day mortality of 2.1% (n [ 1, ZFEN). Major com-
plications occurred in eight patients (17%; two OTS, six ZFEN).
Conclusions: Whereas OTS device strategies will reduce the waiting times for patients with complex aortic aneurysmal
disease, a signiﬁcant number will still require custom-made device repair until additional device designs become available.
Early experience with OTS devices does not demonstrate any signiﬁcant renal risks; however, the treatment numbers are
low and should be interpreted with caution until larger conﬁrmatory studies are published. Further studies comparing the
outcomes of these techniques are required to establish the best approach to handle endovascular repair of complex aortic
aneurysm. (J Vasc Surg 2014;60:579-84.)In April 2012, the U.S. Food and Drug Administration
(FDA) granted approval for the Cook (Bloomington, Ind)
Zenith fenestrated endovascular (ZFEN) graft, providing
technology to the United States that has been routinely
available in Europe and other parts of the world for the
better part of 5 to 8 years. Critical factors in the use of
this graft are procedural expertise, precise planning of the
fenestration locations, and approximately 1 month of
manufacturing time for the device. For asymptomatic elec-
tive aneurysms, this rarely creates an issue with respect to
patient care. However, patients with symptomatic complexthe Division of Vascular Surgery, University of North Carolina.
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://dx.doi.org/10.1016/j.jvs.2014.03.258aortic aneurysms may be placed at increased risk of rupture
if they are expected to wait 4 weeks before receiving deﬁn-
itive treatment. In an effort to address this shortcoming,
“off-the-shelf” (OTS) device conﬁgurations have been
designed. Initial data used to justify their conﬁgurations
and design features were based on a subset of patients
already accepted for Zenith fenestrated devices in Europe
and predicted that 70% of patients may be suitable for
this treatment modality.1 In addition, Endologix (Irvine,
Calif) has developed an alternative design based on no
prior fenestrated device implant experience.2 We report
our experience using these two devices for all patients
referred to our tertiary referral center for the evaluation
and treatment of complex aortic aneurysms with respect
to applicability and generalized outcomes.
METHODS
A prospectively maintained database of aortic proce-
dures was analyzed for patients treated for aortic aneurysms
during the period of July 2012 to September 2013, and
data analysis was conducted through October 2013. Jux-
tarenal and pararenal aneurysms were categorized along
with type IV thoracoabdominal aortic aneurysms (TAAAs)
as was initially described with the categorization of TAAA.3579
Fig. Flow chart showing mechanisms of repair of aneurysms presenting to University of North Carolina Hospitals from
July 2012 to September 2013. TAAA, Thoracoabdominal aortic aneurysm; zFEN, Zenith fenestrated endovascular.
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clinical investigation through investigational device exemp-
tion trials: the Cook p-Branch and Endologix Ventana
device. Patients’ anatomic characteristics were examined to
determine their suitability for each device. Those patients
who were not candidates or chose not to enroll in the trials
were offered alternative treatment strategies, including the
commercially available ZFEN device if applicable on the
basis of manufacturing guidelines. All measurements were
completed on iNtuition software (version 4.4.8; TeraRecon,
San Mateo, Calif) with centerline analysis, and results were
assessed with SAS version 9.3 (SAS Institute, Cary, NC) sta-
tistical analysis software. Reporting standards for the Society
for Vascular Surgery were used in the analysis. The study was
approved by the institutional review board and the FDA
(IDE#-G110101). Patients were exempted from informed
consent for this report based on its retrospective design.
RESULTS
There were 224 aortic repairs completed during this 15-
month period (Fig). This included type II to type IV TAAAs,
thoracic dissections, acute traumatic aortic injuries, and
infrarenal abdominal aortic aneurysms. Excluded from anal-
ysis were isolated thoracic lesions (n ¼ 18), type II and type
III TAAAs (n ¼ 52), and infrarenal repairs (n ¼ 69). The
remaining 85 (38%) type IV TAAAs underwent repair with
the following treatments. Twenty-three patients (27%) were
eligible for OTS devices on the basis of their anatomy. How-
ever, only 16 patients underwent implantation of an OTS de-
vice because ﬁve chose an FDA-approved device and two
chose open repair owing to follow-up requirements.
Twenty-ﬁve additional patients received an FDA-approvedZFEN device, whereas 37 others (44%) did not meet criteria
for any available endovascular device and were repaired with
alternative management strategies, including but limited to
hybrid and open repair, to protect against rupture.
Thirty-seven patients (44%) were excluded primarily
for proximal extension of disease that would compromise
the sealing zone with either a ZFEN or OTS device. Of
the remaining 48 patients, exclusion for OTS devices
(Table I) was a result of severe neck angulation (>60
degrees) in six patients (13%). Overall, only 21% (n ¼ 10)
of the patients met the instructions for use requirements
for the Ventana device; patients were excluded mainly
because of either an insufﬁcient proximal sealing region
below the superior mesenteric artery (SMA; <15 mm;
n ¼ 31; 65%) or renal anatomic criteria (n ¼ 6; 13%).
Conversely, theZenith p-Branch device had a high exclusion
because of renal axial or circumferential position (n ¼ 29;
56%) and more commonly involved exclusion because of
right renal artery position.
The 46 patients treated with either ZFEN or OTS
devices represent the cohort analyzed for outcomes in
this study, with 30 and 16 patients in the respective groups.
Covered stents were routinely used for all fenestrations in
the OTS devices and all ZFEN devices unless early bifurca-
tions prevented their implantation to preserve perfusion.
Self-expanding stents were used to manage branched vessel
kinking at the distal aspect of balloon-expandable stents
at the discretion of the implanting physician. The male-
to-female ratio was approximately 3:1 (76%:24%), with a
similar mean age (M:F, 72.2:73.1 years). Octogenarians
represented 20% of the patients. The maximal aortic diam-
eter based on orthogonal measurement was 59.5 mm. The
Table I. Reason for exclusion from off-the-shelf (OTS)
devices for 48 patients undergoing complex aneurysm
repair
Reason for exclusiona
p-Branch
(eligibility: 40%)
Ventana
(eligibility: 21%)
Neck angulation >60 degrees 13% 13%
Infra-SMA length <15 mm 0% 65%
Renal position 56% 13%
SMA, Superior mesenteric artery.
aPatients may have had more than one exclusion.
Table II. Demographics and comorbid conditions of
46 patients undergoing endovascular repair with either an
off-the-shelf (OTS) or Zenith fenestrated (ZFEN) device
OTS
(n ¼ 16),
No. (%)
ZFEN
(n ¼ 30),
No. (%)
P
value
Mean age 6 SD, years 72 6 6.4 73 6 7.5 NS
Male 14 (87.5) 21 (70) NS
CAD 7 (43.8) 13 (43.3) NS
AFIB 2 (12.5) 4 (13.3) NS
MI 4 (25) 7 (23.3) NS
CHF 1 (6.3) 1 (3.3) NS
CABG/PTCA 5 (31.3) 8 (26.7) NS
Hypertension 13 (81.3) 26 (86.7) NS
Hypercholesterolemia 10 (62.5) 22 (73.3) NS
COPD 10 (62.5) 17 (56.7) NS
Home oxygen 1 (6.3) 3 (10) NS
CRI 3 (18.7) 5 (16.7) NS
Dialysis 0 1 (3.3) NS
Maximal orthogonal aortic
diameter 6 SD, mm
61.3 6 16.1 58.5 6 7.9 NS
AFIB, Atrial ﬁbrillation; CABG/PTCA, coronary artery bypass grafting/
percutaneous transluminal coronary angioplasty; CAD, coronary artery
disease; CHF, congestive heart failure; COPD, chronic obstructive pulmo-
nary disease; CRI, chronic renal insufﬁciency; MI, myocardial infarction;
NS, not signiﬁcant; SD, standard deviation.
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for pre-existing renal insufﬁciency (17%), hypertension
(85%), hypercholesterolemia (70%), and chronic obstruc-
tive pulmonary disease (59%).
Technical success for the entire cohort was 100%, with
a 30-day mortality of 2.1% (n ¼ 1; ZFEN) secondary to a
ruptured hepatic artery aneurysm. No patient experienced
renal failure. Worsening renal function was deﬁned as an
abnormal creatinine concentration with a sustained
decrease in estimated glomerular ﬁltration rate >30% for
more than 3 months. Complications occurred in 18.7%
of the OTS cohort and 16.7% of the ZFEN group and
included pneumonia (n ¼ 1) and worsening renal insufﬁ-
ciency (n ¼ 2) secondary to a procedural renal artery
dissection and renal emboli, both in the OTS cohort.
In the ZFEN group, the complications included the
hepatic artery aneurysm rupture as well as SMA dissection
(n ¼ 1), evacuation of groin hematoma (n ¼ 1), retro-
peritoneal hematoma requiring exploration (n ¼ 1),
arrhythmia (n ¼ 1), groin lymphatic leak (n ¼ 1), and pro-
longed oxygen requirement (n ¼ 1).
Mean follow-up for the cohort was 6.5 months, with
one additional nonaneurysm-related mortality at 72 days.
Device-related secondary interventions (Table III) occurred
in 13% of the patients and did not differ between groups
(P ¼ NS). There were no type I and two type III endoleaks
during the follow-up period. This included a renal artery
fenestration endoleak treated with angioplasty and a mis-
diagnosed type III endoleak from a previous infrarenal de-
vice managed immediately after the index procedure with
extension of the main aortic fenestrated component device.
There were three additional renal artery procedures,
including one renal artery stent extension for distal renal
artery kinking and treatment for severe renal stent steno-
sis/occlusion in two patients. Secondary interventions
were attempted in both instances, with successful restora-
tion of perfusion and maintenance of renal function in
both patients. Imaging analysis demonstrated that these
renal complications were likely the result of a procedure-
related proximal stent kink (managed with tissue plasmin-
ogen activator and balloon angioplasty) and distal renal
artery kinking (treated with a distal self-expanding stent
extension). The additional secondary interventions
included implantation of an SMA stent for extension in
one scallop that was determined to be partially misaligned,
SMA stent insertion for a dissection (n ¼ 1) or proximalextension (n ¼ 1), and embolizations for type II endoleaks
in two patients. Nondevice-related secondary procedures
(13%; n ¼ 6) included two diagnostic arteriograms
obtained for suspicion of visceral artery stenosis based on
duplex surveillance, hypogastric aneurysm exclusion, treat-
ment of an isolated intramural hematoma, carotid endarter-
ectomy, and wound vacuum placement for control of a
groin lymphatic leak.
DISCUSSION
Complex aortic repair is gaining rapid acceptance in the
United States since approval of the Zenith fenestrated
device in April 2012, with more than 500 implants
completed. There is an inherent delay in treatment, how-
ever, given the custom design nature of the device.
Although it is relatively small, a 1-month delay in treatment
of a 6-cm aneurysm would result in an estimated 0.5% to
1% mortality risk in this population, assuming yearly
rupture risk of 6% to 12%.4 This is not insigniﬁcant, how-
ever, when one considers that the treatment risk in most
experienced hands is 0% to 5% for fenestrated repairs.5 In
an effort to reduce the overall risk as low as possible,
OTS device designs have been proposed and are in early
clinical trials. To reduce the mortality risk associated with
a delay in treatment, however, the devices must be able
to treat a signiﬁcant portion of the patients for whom
they are designed without signiﬁcantly increasing the other
risks associated with the repair.
Initial design efforts were based on patients being
treated with a custom-designed ZFEN device1 and esti-
mated 70% applicability in the patient population. This,
however, was based on a preselected group. In our tertiary
Table III. Secondary interventions among 46 patients
undergoing endovascular repair with either an off-the-
shelf (OTS) or Zenith fenestrated (ZFEN) device
Device related: 13%
Type III repair, distal aortic
extension: 1
3 days
Renal artery interventions: 4
PTA for type III endoleak: 1 1.5 months
RA stent extension for kinking: 1 6 months
Severe stent stenosis/occlusiona:2 1 month, 4 months
SMA stent for extension or
malalignment: 2
5 months, 6 months
SMA stent extension for dissection:
1
3 hours
Type II endoleak embolization: 2 7 months, 12 months
Other: 13%
Diagnostic visceral angiogram: 2 4 months, 9 months
Thoracic IMH treatment: 1 1 month
Hypogastric aneurysm exclusion: 1 2 months
Carotid endarterectomy: 1 7 months
Wound vacuum placement for
control of lymphatic leak: 1
1 month
IMH, Intramural hematoma; PTA, percutaneous transluminal angioplasty;
RA, renal artery; SMA, superior mesenteric artery.
aPrimary procedure-related stent kinking; both treated with tissue plas-
minogen activator and angioplasty.
JOURNAL OF VASCULAR SURGERY
582 Farber et al September 2014referral center for complex aneurysms, we evaluated all
patients undergoing treatment at our institution. After
excluding isolated thoracic aneurysms, type II and type
III TAAAs, thoracic transection, and infrarenal patho-
logic processes, we were left with 85 potential candidates
with type IV TAAAs, including pararenal and paravisceral
subtypes. Analysis in this cohort resulted in an applica-
bility percentage of 27%, which is vastly different from
that originally reported. To aid in future device develop-
ment, it is important to understand why exclusions
occurred. For a device designed to treat paravisceral aneu-
rysms (Zenith p-Branch), restrictions in the renal treat-
ment zone occur because the design is based on a ﬁxed
SMA position. The speciﬁcs of the device have been pre-
viously reported.6 This is an intentional design feature
to ensure patency of the most critical visceral vessel,
which is always treated with a covered stent through
the fenestration. In contrast, a design that targets parare-
nal aneurysms (Endologix Ventana device) has signiﬁcant
limitations in treating more extensive proximal disease
but liberates the strict anatomic criteria seen in a paravisc-
eral device. Whereas each device had its design advantages
and disadvantages, the p-Branch device can be adapted to
more patients (40%) compared with the Ventana device
(21%). These ﬁndings are similar to those reported by
Oderich et al7 and do not include patients presenting
with type IVTAAAs in which the proximal extent of disease
extended cranially above the level of the SMA (n ¼ 37).
This is a reﬂection of our conservative philosophy concern-
ing endovascular management of patients with aortic
disease. Our belief is that aortic enlargement as one pro-
gresses caudally down the aorta of more than 10% repre-
sents early aneurysmal disease, and this region should be
avoided as the intended sealing zone in patients and thedevice implanted more proximally. This suggests that
nearly half (43%; 37 of 85) of those patients diagnosed
with type IVTAAAswould require devices that use a sealing
region in the distal descending thoracic aorta and incorpo-
rate all four visceral vessels into the treatment strategy.
This type of conﬁguration is not currently available in the
United States, even with custom-designed conﬁgurations.
In addition, the only OFS solution in management of these
patients as well as of patients with type II and type III
TAAAs appears to be the standardized thoracic branched
device described by Chuter.8 This is not without contro-
versy, however, as some individuals believe that upward-
angled renal vessels can be problematic with caudally
oriented branches.9
There has always been some concern that more exten-
sive fenestrated endovascular aortic aneurysm repair would
lead to a high incidence of complications. We experienced
branched stent event rates in the OTS and ZFEN cohorts
of 6.5% (3 of 46) and 5.9% (4 of 68), respectively. This is in
the range of previously published reports (5%-25%)8,10 and
highlights the importance of close postoperative surveil-
lance and attention to detail in this group of complex pa-
tients. Whereas we report no renal occlusive event in our
custom fenestrated population, they have previously been
reported.9 The two renal occlusive events in the OTS
cohort can be attributed to the learning curve of new de-
vices. The severe stenosis that was observed at 1-month
follow-up in the p-Branch device was procedure related.
Review of the primary procedure revealed an anterior to
posterior crushing of the left renal stent during insertion of
the distal aortic component. This was treated with a short
period of tissue plasminogen activator and redilation of the
proximal renal stent. The patient’s renal function has
remained below his baseline at his 6-month follow-up visit.
Since this event, we have changed our practice either
routinely to re-balloon the renal stents at risk for crushing
or to perform a completion 3D/Dyna-CTA (Siemens Med-
ical Solutions, Erlangen, Germany) to conﬁrm that no
branched stent vessel issues exist before completing the pri-
mary procedure. In the second instance, renal occlusion
occurred at 3months in a patient with a Ventana device. Im-
aging analysis of the procedure and postoperative ﬁlms sug-
gested kinking at the distal end of the stent despite normal
renal velocity criteria. Reintervention was again successful
in re-establishing perfusion of the patient’s renal function,
with normalization of his renal function at 3 months.
Additional efforts at decreasing delays in treatment are
forthcoming. Type II and type III TAAAs can potentially
be managed with either an OTS four-vessel branched de-
vice or a hybrid device using both fenestrations and
branches.8,11 For pararenal and paravisceral subtypes, how-
ever, additional efforts may need to be targeted at addi-
tional conﬁgurations of devices. The p-Branch device is
currently offered in two different options: one with the
renal artery pivot fenestrations at the same level and the
second with the left renal artery positioned lower. Exclu-
sion analysis reveals that many right renal arteries are within
5 mm longitudinally of the base of the SMA. Adjustments
JOURNAL OF VASCULAR SURGERY
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treatment of these patients.
Whereas the current Ventana device trial is on hold as
of this writing, our data suggest that future design efforts
should be targeted at improvement in the proximal sealing
region in an attempt to treat paravisceral aneurysms
because it appears to have a sufﬁcient incorporation of renal
vessel locations. Attempting to use OTS devices outside
their intended instructions for use would deﬁnitely increase
the eligibility of patients but in our opinion signiﬁcantly
increases the risk of device-related complications. Each of
the aforementioned OTS devices differ in the intended
proximal sealing regions. The p-Branch device is able to
treat paravisceral aortic disease that extends to the base of
the SMA by using a fenestration for the SMA and a scallop
for the celiac artery. The Ventana device, on the other
hand, needs a 15-mm infra-SMA neck length because of
the large scallop conﬁguration, limiting it to the treatment
of pararenal aneurysms.
There were some limitations of this study. There were a
limited number of patients who had OTS implants. Further
studies with increased sample size and longer follow-up are
needed to prove that these devices are safe. We evaluated
only complex aneurysms referred to our center. Types of
aneurysms referred may be different at other institutions
and may have changed the results of our analysis. The im-
plants were also done at an institution with vast experience
in performing complex fenestrated endovascular repair.
These results and the learning curve may be different in
less experienced hands.
CONCLUSIONS
Whereas OTS device strategies will reduce the waiting
times for patients with complex aortic aneurysmal disease,
a signiﬁcant number will still require either complex open
or endovascular custom-made devices until additional de-
vice designs become available. Early experience with OTS
devices does not demonstrate any signiﬁcant renal risks;
however, the treatment numbers are low and should be
interpreted with caution until larger conﬁrmatory studies
are published. Further studies comparing the outcomes of
these techniques are required to establish the best approach
to handle endovascular repair of complex aortic aneurysm.
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excellent presentation, and congratulations on a nice manuscript.
This study demonstrates the difﬁculties that device engineers
and surgeons alike will have with expanding endovascular repair
to the branched segments of the aorta, particularly with ﬁnding de-
vices that do not have to be customized to the patient’s individual
anatomy.
Because of the wide variation in aneurysm location and the
variability of the visceral vessel anatomy, Dr Farber has demon-
strated that the current conﬁgurations of off-the-shelf (OTS)devices are unable to treat the majority of patients for whom
they were designed. He has also demonstrated that when these de-
vices do accommodate the patient’s anatomy within their intended
conﬁguration, they do a nice job of providing an adequate repair in
early follow-up.
Mark, I have two questions for you:
1. Where are these OTS devices going to go in the future? With
the current technology used in these devices, do you think we
will ever be able to reach the device companies’ goal of treat-
ing 60% to 70% of patients?
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aorta, we are obviously worried about whether you can suc-
cessfully complete the repair with regard to the visceral and
renal anatomy, but what is your philosophy about what consti-
tutes good aorta for a landing zone proximally? For example,
with juxtarenal and suprarenal aneurysms, why not always use
the distal thoracic aorta as a landing zone to ensure that you
are providing a good zone of seal and ﬁxation? Is there any
downside to that?
DrMark A. Farber. Thanks, Adam. I think I will handle your
second question ﬁrst about the scallops. First a commentdnot all
scallops are the same. If you look at the Ventana device, it is a very
large, wide scallop. It is what most of us would probably refer to as
a double-wide scallop. It is on the order of 20+ mm in width and
very deep. The current custom ZFEN device is a very narrow
scallop of only 10 mm. We as well as others in the United States
have changed our practice about how we manage very small scal-
lops. They can be malaligned, needing a superior mesenteric artery
stent, which is not the case for double-wide scallops. So we have to
be careful about saying scallops are all the same. I think all of us
know that as you become more comfortable doing these proce-
dures moving up into the SMA and the celiac, it does not add sig-
niﬁcant risk. It does not add that much more time, and it is more
about selecting the right patient. If you take some of the early data
from the Cleveland Clinic, their failures were in patients who
already had some minor dilation of the aortic neck in the paravisc-
eral section at the SMA, and so we have used centerline ﬂow anal-
ysis to plan; and whenever any signiﬁcant change is seen, 10% or
posterior disease in the aorta, we move our sealing zone up into
the distal thoracic aorta to try to get away from that. The problem
is access to devices that accomplish this, and if people try to shoe-
horn a device in a problem area, it is going to be more prone to
fail. I am sure your institution and many referral institutions are
the same. We see failed infrarenal devices, and if you go back to
the original imaging, the device was put in an already diseased
infrarenal neck, and that goes on to dilate and fail. I think from
that standpoint and to where we are going in the future, it ties into
your ﬁrst question. We will move up, but we will move up whenthe devices are available, and doing a four-vessel fenestration,
thereby giving yourself a 3-cm landing zone above the celiac, means
that any future repair is going tobemuch easier because you can atta-
ch that into a tube graft.
Your last question, what is the FDA thinking? Well, I do not
really know what the FDA is thinking. To say that it will let us do
these OTS devices I think is a little stretch. They are done under
investigational device exemption protocols, and I think we do
have to look at outcomes. If we take OTS devices that have a lim-
itation where you can put the renals and the SMA and say “we are
going to cheat on that and maybe we will move it here” for an ur-
gent or emergent case and we cannot wait for a custom-designed
device to ﬁt the patient speciﬁcally, then we have to assess the risks.
If the risks are that the patient has one renal and the renal does not
ﬁt and that the patient is going to go into renal failure if the device
does not ﬁt, then I think that is a lot different from someone who
says “well, there is an accessory renal and we are going to lose part
of a kidney function, not the whole function, and we can deal with
that.” I think this is going to be up to the individuals about how to
use it. If we use the devices inappropriately, eventually it is going to
ultimately hurt us in the outcome. I think most of us believe that
custom devices are still going to play a role, and in our practice I
think it is probably going to be 50/50 custom devices vs OTS
devices, unless we can get more designs to ﬁt more people, then
that may increase to 70%. The original 70% estimate on applica-
bility was based only on devices that were ordered out of Tim
Resch’s group in Sweden for a custom device. So he already
took out the pararenal, the paravessels, and unusual cases. What
we tried to look at is what comes to our practice because our
goal is to send a message to the corporations that this is what
we need to treat more patients in an off-the-shelf fashion. We
have to look at the renals closely, of which the right renal artery
is the most problematic. It actually comes up very high, and for
the p-Branch device, that interferes with the SMA stent, and
then the Ventana device does not extend high enough into the
aorta because of that wide scallop. So the message will be different
per device as to what needs to be modiﬁed to treat more patients,
but that is really what we are after.
